Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

ion during 2006. The decrease in R&D

expenses was primarily attributable to the CETHRIN license fee of $10

million in 2006.

-- General and administrative (G&A) expenses were $8.4 million in 2007 as

compared to $7.9 million in 2006. The increase in G&A expenses was

primarily related to higher commercialization and communication costs

and higher headcount offset by lower costs related to our collaboration

and fundraising efforts.

Conference Call Access Information

The Company will host a conference call to discuss results on, April 1,

2008, at 10:00 a.m. Eastern Daylight Time. The call can be accessed by

dialing dial 877-718-5104 (or 719-325-4843 for international

participants). The participant pass code for this conference call is

7767549. Please dial in 5 to 10 minutes prior to the scheduled start

time. A replay of the call will be posted on the Investor Relations

section of the website, http://www.alseres.com, within 48 hours following

the conference call and will be available through Tuesday, April 15, 2008.

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. CETHRIN, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative ther
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... SAN MATEO, Calif., Nov. 3 Top-line preliminary ... investigational drug,relaxin for the treatment of acute heart ... symposium at the American Heart Association,s (AHA),Scientific Sessions ... M.D., Professor of Medicine, University of California,San Francisco, ...
... CAMBRIDGE, Mass., Nov. 3 Verenium Corporation,(Nasdaq: ... next-generation cellulosic,ethanol and high-performance specialty enzymes, announced today ... on Monday, November 10,2008 after market close. In ... conference call with live webcast on Monday, November ...
... SAN FRANCISCO, Calif., Nov. 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for,the treatment of ... be presenting at the following upcoming conferences:, Rodman ... York Palace Hotel, New York, Wednesday, November 12, ...
Cached Biology Technology:Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 3Sunesis to Present at Upcoming Conferences 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... specially synthesized boron compounds are readily accepted in biologically ... proof of concept that could lead to new drug ... chemist Shih-Yuan Liu reported in the Journal of ... boron-nitrogen compounds with electronic and structural similarities to fundamentally ...
... Scientists in Michigan are reporting the development of a powerful ... process important in aging and disease. The probe works like ... cells. It could lead to new insights into disease processes ... Their study is scheduled for the Sept. 18 issue of ...
... COLUMBUS, Ohio Scientists here are the first to demonstrate ... in the ability of diesel exhaust to induce the growth ... for solid tumors. The researchers found that in both ... mice exposed to diesel exhaust than did in mice exposed ...
Cached Biology News:Boron-based compounds trick a biomedical protein 2Diesel exhaust is linked to cancer development via new blood vessel growth 2Diesel exhaust is linked to cancer development via new blood vessel growth 3Diesel exhaust is linked to cancer development via new blood vessel growth 4
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 148 cm 2 Mfr Desig: ...
Biology Products: